Table 3.
Multivariate Cox regression analysis for overall survival
| Characteristics | HR (95% CI) | P value |
|---|---|---|
| ECOG-PS (≥2 versus 0-1) | 2.50 (1.24-5.03) | 0.01 |
| Metastatic sites (increment of one site) | 1.14 (0.77-1.69) | 0.51 |
| Lymph node metastases (yes versus no) | 0.72 (0.35-1.49) | 0.38 |
| Liver metastases (yes versus no) | 1.97 (0.89-4.36) | 0.09 |
| Bone metastases (yes versus no) | 1.40 (0.71-2.75) | 0.33 |
| Brain metastases (yes versus no) | 3.88 (0.53-28.51) | 0.18 |
| Peritoneal metastases (yes versus no) | 2.40 (1.08-5.33) | 0.03 |
| LDH (>ULN versus ≤ULN) | 0.93 (0.52-1.64) | 0.79 |
| Albumin (<3.5 g/dl versus ≥3.5 g/dl) | 2.36 (1.14-4.90) | 0.02 |
| Hemoglobin (<10 g/dl versus ≥10 g/dl) | 1.99 (1.02-3.89) | 0.04 |
| dNLR (≥3 versus <3) | 1.69 (0.91-3.13) | 0.09 |
| Antibiotic use (yes versus no) | 1.59 (0.73-3.45) | 0.24 |
| PPI use (yes versus no) | 1.83 (1.11-3.02) | 0.02 |
Bold numbers indicate statistically significant values.
CI, confidence interval; dNLR, derived neutrophil-lymphocyte ratio; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; HR, hazard ratio; LDH, lactate dehydrogenase; PPI, proton-pump inhibitors; ULN, upper limit of normal.